IPO bound? Crossovers join big syndicate backing Precision BioSciences’ $110M gene editing round
With a base in Durham, NC, Precision BioSciences has managed to stay off the gene-editing radar that has spotlighted some of the leading players in the field. But that doesn’t mean that investors have been ignoring the work.
On Wednesday a broad mix of investors — including some notable crossovers — wrapped a $110 million raise for the biotech, putting them in the big leagues in terms of the mega-money flowing in that direction these days. Once a rare sight, these big raises have become almost routine in biotech this year, especially when tied to something as hot as a gene editing platform.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
